ID   Hs 445
AC   CVCL_0761
SY   HS-445; Hs-445; HS 445T; Hs445; HS445
DR   CLO; CLO_0003962
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-146
DR   BioSample; SAMN03472720
DR   Cell_Model_Passport; SIDM00668
DR   Cosmic-CLP; 1322218
DR   DepMap; ACH-002245
DR   EGA; EGAS00001000978
DR   GDSC; 1322218
DR   GEO; GSM1669894
DR   LINCS_LDP; LCL-2006
DR   PharmacoDB; Hs445_613_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54895678
RX   PubMed=6500159;
RX   PubMed=11021758;
RX   PubMed=12592342;
RX   PubMed=27397505;
RX   PubMed=29533902;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Problematic cell line: Misclassified. Originally thought to be a Hodgkin lymphoma cell line but is a B-lymphoblastoid cell line (PubMed=12592342; PubMed=29533902).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Caucasian.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=0.48%; Native American=0%; East Asian, North=1.04%; East Asian, South=0.01%; South Asian=0%; European, North=63.69%; European, South=34.78% (PubMed=30894373).
CC   Derived from site: In situ; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ATCC=HTB-146; Cosmic-CLP=1322218
ST   Amelogenin: X
ST   CSF1PO: 10.3,11 (ATCC=HTB-146)
ST   CSF1PO: 11 (Cosmic-CLP=1322218)
ST   D13S317: 11,13
ST   D16S539: 9 (Cosmic-CLP=1322218)
ST   D16S539: 9,11 (ATCC=HTB-146)
ST   D18S51: 13,15
ST   D19S433: 14
ST   D21S11: 29,31
ST   D2S1338: 20,24
ST   D3S1358: 16,18
ST   D5S818: 9,12
ST   D7S820: 9,10
ST   D8S1179: 14
ST   FGA: 24,26
ST   Penta D: 10,11
ST   Penta E: 12,14
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 14,17
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Transformed cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 32
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M.J., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=12592342; DOI=10.1038/sj.leu.2402799;
RA   Drexler H.G., Dirks W.G., Matsuo Y., MacLeod R.A.F.;
RT   "False leukemia-lymphoma cell lines: an update on over 500 cell
RT   lines.";
RL   Leukemia 17:416-426(2003).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=29533902; DOI=10.1515/hsz-2017-0321;
RA   Drexler H.G., Pommerenke C., Eberth S., Nagel S.;
RT   "Hodgkin lymphoma cell lines: to separate the wheat from the chaff.";
RL   Biol. Chem. 399:511-523(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//